In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days
- PMID: 31207620
- DOI: 10.7326/ACPJ201906180-067
In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days
Comment on
-
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. N Engl J Med. 2019. PMID: 30786186 Clinical Trial.
Similar articles
-
Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.J Korean Med Sci. 2019 Jun 2;34(21):e160. doi: 10.3346/jkms.2019.34.e160. J Korean Med Sci. 2019. PMID: 31144482 Free PMC article.
-
Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study.PLoS One. 2017 May 24;12(5):e0178214. doi: 10.1371/journal.pone.0178214. eCollection 2017. PLoS One. 2017. PMID: 28542415 Free PMC article.
-
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.Thromb Haemost. 2016 Jun 2;115(6):1240-8. doi: 10.1160/TH15-09-0756. Epub 2016 Feb 4. Thromb Haemost. 2016. PMID: 26842902 Clinical Trial.
-
Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.Hosp Pract (1995). 2018 Feb;46(1):5-15. doi: 10.1080/21548331.2018.1410053. Epub 2017 Nov 30. Hosp Pract (1995). 2018. PMID: 29171776 Review.
-
Rivaroxaban for prevention and treatment of venous thromboembolism.Future Cardiol. 2019 Mar;15(2):63-77. doi: 10.2217/fca-2018-0076. Epub 2019 Feb 19. Future Cardiol. 2019. PMID: 30779598 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources